OncoMatch/Clinical Trials/NCT03180268
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Is NCT03180268 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for grade 2 meningioma.
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage WHO GRADE II (WHO 2016)
Grade: II (WHO 2016)
WHO grade II based upon pathology findings at the enrolling institution. WHO grade will be assigned according to WHO 2016 criteria
Performance status
ZUBROD 0–1
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Saint Joseph's Hospital and Medical Center · Phoenix, Arizona
- Mayo Clinic Hospital in Arizona · Phoenix, Arizona
- Mayo Clinic in Arizona · Scottsdale, Arizona
- University of Arizona Cancer Center-Orange Grove Campus · Tucson, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify